© Drug Hunter Inc. 2018-2023
Home > CC-90011
selective, reversible LSD1 inhibitor
<100 mg orally QW, in Ph. II for 1L ES-SCLC
from 300k+ cmpd HTS, SBDD + opt.
J. Med. Chem., Oct. 9, 2020
Celgene/Bristol Myers Squibb, San Diego, CA
CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year